Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo- RAS -Wildtype Metastatic Colorectal Cancer Is Transient
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00031 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Florence T H Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE In metastatic colorectal cancer (mCRC), RAS mutations drive resistance to anti–epidermal growth factor receptor antibodies. It is unclear whether RAS mutations ever become clonally undetectable. METHODS CO.26 was a phase II clinical trial that assessed durvalumab + tremelimumab in heavily pretreated mCRC. RAS mutation status was tracked over time using circulating tumor DNA (ctDNA) sequencing at baseline, week 8, and on progression. RESULTS Among the 95 patients with KRAS/NRAS mutations in their archival tumor tissue, 6.3% (6/95) had undetectable RAS mutations in ctDNA collected at baseline or week 8 of the CO.26 study. Of these, 67% (4/6) of disappearances were transient, with the same mutation reappearing with progressive disease. In three cases, the simultaneous persistence of other preexisting CRC-associated truncal mutations could not be demonstrated, suggestive of low tumor shedding of ctDNA, leaving the incidence of true clonal reversion to RAS-wildtype (WT) possibly as low as 3.2% (3/95). Fewer patients in the neo- RAS-WT group (33%) had greater than four lesions at trial baseline compared with patients with persistent RAS mutations (75%), P = .046. The likelihood of synchronous metastases at cancer diagnosis (33% v 63%; P = .15) or liver metastases at trial baseline (50% v 68.5%; P = .17) was not significantly different between patients with disappearing versus persistent RAS mutations. Overall survival from stage IV diagnosis (hazard ratio, 0.77 [95% CI, 0.35 to 1.72]; P = .52) was not significantly different between those with disappearing versus persistent RAS mutations. The disappearance of RAS mutations was not associated with primary tumor sidedness ( P = .41), archival BRAF/MEK/ERK-mutant status ( P = .16/1.00/.09), nor baseline ctDNA HER2 amplifications ( P = 1.00). CONCLUSION We identified a 3.2%-6.3% prevalence of the neo- RAS-WT phenomenon in the CO.26 trial. However, 67% of apparent cases were transient with subsequent re-emergence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- BC Cancer, University of British Columbia, Vancouver, BC, Canada.
- Canadian Cancer Trials Group, Kingston, ON, Canada.
- Oregon Health & Science University, Portland, OR.
- Guardant Health, Redwood City, CA.
- The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
- Princess Margaret Cancer Centre, Toronto, ON, Canada.
ORCID-Profile: Florence T H Wu, Harriet Feilotter, Hagen F Kennecke, Dongsheng Tu, Eric X Chen, Jonathan M Loree
Zitieren
APA
Wu, F. T. H., Topham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Drusbosky, L., Renouf, D. J., Jonker, D. J., Tu, D., Chen, E. X., & Loree, J. M. (2024). Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo- RAS -Wildtype Metastatic Colorectal Cancer Is Transient. JCO Precision Oncology. https://doi.org/10.1200/po.24.00031
Vancouver
Wu FTH, Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Drusbosky L, et al. Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo- RAS -Wildtype Metastatic Colorectal Cancer Is Transient. JCO Precision Oncology. 2024. doi:10.1200/po.24.00031
BibTeX
@article{Wu2024,
author = {Wu, Florence T H and Topham, James T and O'Callaghan, Chris J and Feilotter, Harriet and Kennecke, Hagen F and Drusbosky, Leylah and Renouf, Daniel J and Jonker, Derek J and Tu, Dongsheng and Chen, Eric X and Loree, Jonathan M},
title = {Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo- RAS -Wildtype Metastatic Colorectal Cancer Is Transient},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00031}
}
EUVIMED